Northstar Asset Management Inc. Buys 190 Shares of Danaher Co. (NYSE:DHR)

Northstar Asset Management Inc. grew its stake in shares of Danaher Co. (NYSE:DHR) by 0.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,654 shares of the conglomerate’s stock after acquiring an additional 190 shares during the period. Danaher accounts for 2.4% of Northstar Asset Management Inc.’s holdings, making the stock its 18th largest position. Northstar Asset Management Inc.’s holdings in Danaher were worth $9,635,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently made changes to their positions in DHR. Marks Group Wealth Management Inc increased its position in Danaher by 5.0% during the 3rd quarter. Marks Group Wealth Management Inc now owns 4,660 shares of the conglomerate’s stock worth $1,296,000 after buying an additional 223 shares during the period. Balentine LLC acquired a new position in shares of Danaher during the 3rd quarter worth approximately $420,000. Crestwood Advisors Group LLC raised its position in shares of Danaher by 0.4% in the third quarter. Crestwood Advisors Group LLC now owns 333,248 shares of the conglomerate’s stock valued at $92,649,000 after buying an additional 1,264 shares in the last quarter. Pittenger & Anderson Inc. boosted its stake in shares of Danaher by 3.2% in the third quarter. Pittenger & Anderson Inc. now owns 67,823 shares of the conglomerate’s stock valued at $18,856,000 after buying an additional 2,116 shares during the period. Finally, Sentry Investment Management LLC increased its stake in Danaher by 65.6% during the 3rd quarter. Sentry Investment Management LLC now owns 3,086 shares of the conglomerate’s stock worth $858,000 after acquiring an additional 1,223 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR stock opened at $250.16 on Wednesday. The business has a 50-day simple moving average of $266.16 and a two-hundred day simple moving average of $260.84. Danaher Co. has a 52-week low of $192.35 and a 52-week high of $281.70. The company has a market capitalization of $180.68 billion, a P/E ratio of 47.74, a price-to-earnings-growth ratio of 4.55 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the company posted $2.02 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. Research analysts expect that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s payout ratio is 20.61%.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 10.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. KeyCorp boosted their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Stephens reissued an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. The Goldman Sachs Group upped their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Stifel Nicolaus boosted their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Finally, Royal Bank of Canada reduced their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.